Tài liệu Báo cáo khoa học: Cytochrome P450 Cyp4x1 is a major P450 protein in mouse brain doc

Cytochrome P450 Cyp4x1 is a major P450 protein
in mouse brain
Mohammed Al-Anizy
1
, Neill J. Horley
1
, C W. S. Kuo
1
, Lorna C. Gillett
2
, Charles A. Laughton
2
,
David Kendall
3
, David A. Barrett
2
, Terry Parker
3
and David R. Bell
1
1 School of Biology, University of Nottingham, UK
2 School of Pharmacy, University of Nottingham, UK
3 School of Biomedical Sciences, University of Nottingham, UK
Cytochromes P450 are a superfamily of proteins [1]
which are involved in the oxidative metabolism of both
foreign and endogenous compounds [2]. The cyto-
chrome P450 4A family is known to be highly induced
by peroxisome proliferators in mouse liver [3,4],
although there is constitutive expression of one gene
[5]. The CYP4A [6], CYP4B [7,8] and CYP4F [9,10]

proteins are known to have fatty acid hydroxylase
activity, and there is extensive speculation that the
formation of hydroxylated fatty acids by cytochrome
P450 leads to the production of physiologically active
metabolites that regulate physiological function [11–16].
Cytochrome P450 metabolism of fatty acids may also
be of fundamental importance in brain [17–19], and it
is known that neurotransmitters and fatty acids can be
actively metabolized by cytochrome P450 in brain
[18,20,21]. Although the specific content of cytochrome
P450 in brain is relatively low compared with liver
[17,22,23], this level of cytochrome P450 can be induced
by various agents [24]. A peculiar feature of brain P450
is that it is difficult to account for the total P450 con-
tent with previously characterized P450 proteins [17].
We describe the cloning of human and mouse
cDNAs for the CYP4x1 P450, a molecular model of
the protein, and tissue-specific localization of the RNA
in mouse and human. The Cyp4x1 protein was locali-
zed by immunohistochemistry and shown to be a
major P450 protein in mouse brain.
Keywords
Cytochrome P450; peroxisome proliferators;
brain; aorta
Correspondence
D.R. Bell, School of Biology, University of
Nottingham, University Park, Nottingham.
NG7 2RD, UK
Fax: +44 115 9513251
Tel: +44 115 9513210

E-mail:
(Received 16 November 2005, revised 20
December 2005, accepted 23 December
2005)
doi:10.1111/j.1742-4658.2006.05119.x
A novel cytochrome P450, CYP4x1, was identified in EST databases on
the basis of similarity to a conserved region in the C-helix of the CYP4A
family. The human and mouse CYP4x1 cDNAs were cloned and found
to encode putative cytochrome P450 proteins. Molecular modelling of
CYP4x1 predicted an unusual substrate binding channel for the CYP4 fam-
ily. Expression of human CYP4x1 was detected in brain by EST analysis,
and in aorta by northern blotting. The mouse cDNA was used to demon-
strate that the Cyp4x RNA was expressed principally in brain, and at much
lower levels in liver; hepatic levels of the Cyp4x1 RNA were not affected
by treatment with the inducing agents phenobarbital, dioxin, dexametha-
sone or ciprofibrate, nor were the levels affected in PPARa– ⁄ – mice. A
specific antibody for Cyp4x1 was developed, and shown to detect Cyp4x1
in brain; quantitation of the Cyp4x1 protein in brain demonstrated  10 ng
of Cyp4x1 proteinÆmg
)1
microsomal protein, showing that Cyp4x1 is a
major brain P450. Immunohistochemical localization of the Cyp4x1 protein
in brain showed specific staining of neurons, choroids epithelial cells and
vascular endothelial cells. These data suggest an important role for Cyp4x1
in the brain.
Abbreviations
DAB, 3,3¢-diaminobenzidine; TCDD, 2,3,7,8 tetrachlorodibenzo-p-dioxin.
936 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
Results
Identification of human CYP4x1

We previously noted that members of the murine
Cyp4a subfamily showed high conservation of the
protein sequence in exon 4, amino acids 125–167 of
Cyp4a10 [4]. A more comprehensive alignment of
CYP4 family proteins was undertaken (Fig. 1A), which
confirmed the high conservation of this region of the
protein sequence. CYP4A1 has been modelled based
on CYP102 (C.A. Laughton, unpublished data), and
this model suggests that this region is a part of the
C-helix, which may be involved in making conserved
contacts with conserved residues in the I-helix. To test
whether this sequence was conserved, we used a
BLAST search of Uniprot (,
June 2005) with residues 124–158 of rat CYP4A1,
which detected putative members of the CYP4 family.
Interestingly, this search also detected unknown,
putative human CYP4 transcripts, R53456, which was
sequenced, leading to the identification of further EST
clones, AA337301 and AA319338. The full-length
cDNA for this gene was cloned by screening of a
human aorta cDNA library, and RT ⁄ PCR, and yielded
a full-length clone, which was then sequenced on both
strands (EMBL Accession number AM040940). This
cDNA encodes an ORF of 509 amino acids, a predic-
ted molecular mass of 58 874 Da, a pI of 8.5, and has
been designated CYP4x1 on the basis of 70% amino
acid identity to the rat CYP4x1 (Fig. 1B). While this
work was in preparation, this sequence has been cloned
[25] and described in bioinformatics analysis [26] by
others.

The predicted CYP4x1 protein has characteristics of
a functional P450, including conservation of the haem-
binding cysteine in the RNCIG motif, and so we
undertook molecular modelling to examine its struc-
ture. The model was based on the crystal structure of
the fatty-acid binding P450 from Bacillus megaterium
CYP102 (PDB code 1FAG) [27], with which it shares
a 21% amino acid identity. The model suggests that
CYP4x1 has an active site cavity that is rather differ-
ent in shape from that of CYP102 (Fig. 2).
The expression of CYP4x1 was investigated by nor-
thern blotting using an EcoRI cDNA fragment from
bases 91–1389 of the cDNA which was radiolabelled
by random priming. As shown in Fig. 3A, there was
expression of CYP4x1 RNA in brain, heart and kid-
ney, and lesser expression in skeletal muscle and liver,
and no detectable expression in other tissues. However,
probing of a blot of heart tissues showed that there
was minimal expression in heart, but high level expres-
sion in aorta (Fig. 3B). Sixty-five CYP4x1 ESTs were
detected in a database search (07 ⁄ 05), and of these, 18
were from brain, three were from aorta and 21 were
from tumours or cell lines, confirming the importance
of brain and aorta as sites of expression.
Cloning of mouse Cyp4x1
To be able to work with an experimentally tractable
species, the mouse Cyp4x1 cDNA was cloned from
brain RNA of 129S4 ⁄ Jae mice, based on the mouse
genomic sequence (AJ297131). A full-length cDNA
was cloned and sequenced (EMBL Accession number

AJ786769), encoding a putative protein of 507 amino
acids, a molecular weight of 58 556 Da, a pI of 7.19,
with 94 and 71% identity with the rat and human
CYP4x1 proteins, respectively (Fig. 1B). A genomic
fragment of the CYP4x1 was cloned, containing
247 bp of intron and 177 bp of exon, and was used for
RNAase protection assays. The specificity was con-
firmed by the finding that yeast tRNA failed to protect
the probe sequence (Fig. 4A), but there was high-level
specific protection of 177 bp of the probe by mouse
brain RNA, whereas liver RNA showed very low-level
protection of the 177-bp fragment. The protection of a
fragment of 177 bp demonstrates that the protection
of the probe is specific for the size of the exon frag-
ment, and is therefore specifically detecting the expres-
sion of Cyp4x1 RNA. The inability of yeast tRNA to
protect the Cyp4x1 probe shows that the RNAase
protection is highly specific, consistent with previous
reports (e.g. [3,28]). Numerous members of the CYP4
family are known to show liver-specific expression or
induction (e.g. in mouse [3,4]), so we determined if the
Cyp4x1 RNA was inducible by treatment of mice
with the classical inducers 2,3,7,8-tetrachlorodibenzo-
p-dioxin, phenobarbital, dexamethasone or ciprofi-
brate. As shown in Fig. 4B, there was a low level of
expression of Cyp4x1 in control mice, but no hepatic
induction of Cyp4x1 RNA after treatment with these
inducers, nor was the level of Cyp4x1 RNA perturbed
in liver RNA from PPARa– ⁄ – mice [29]. Extrahepatic
expression of Cyp4x1 was also investigated. As shown

in Fig. 4C, heart, lung, kidney and spleen showed very
low levels of expression, whereas there was expression
in aorta (Fig. 4D). The highest levels of expression
were shown in brain (Fig. 4E) from 129S4 ⁄ Jae mice,
and the levels of expression were comparable in brain
RNA from PPARa– ⁄ – mice. Treatment of mice
with the classical inducers 2,3,7,8-tetrachlorodibenzo-
p-dioxin, phenobarbital, dexamethasone or ciprofi-
brate, had no effect on the expression of Cyp4x1 in
brain (data not shown).
M. Al-Anizy et al. Cyp4x1 in mouse brain
FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 937
A
B
Fig. 1. Alignment of CYP4 family sequences. (A) Mammalian CYP4 protein sequences were optimally aligned, then displayed using GENEDOC,
with black squares at 90%, dark grey squares at 75% and light grey square at 60% amino acid identity. Sequences are identified by gene
name, with the exception of rabbit CYP4B1 (cyp4b1), rat CYP4B1 (cyp4b1) and human CYP4B1 (cyp4b1). The conserved region is under-
lined. (B) Alignment of deduced amino acid sequence of rat, human and mouse CYP4x1 proteins.
Cyp4x1 in mouse brain M. Al-Anizy et al.
938 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
Expression of Cyp4x1 protein
To analyse the expression of Cyp4x1 protein, a full-
length clone of mouse Cyp4x1 was inserted into the
pRSETa expression vector (Invitrogen, Paisley, UK),
and insoluble recombinant protein was affinity purified
from bacteria (Fig. 5A). Polyclonal antisera raised
against the human CYP4x1 [25] bound to the mouse
protein with low affinity, and could not be used for
studies in mice (data not shown). The mouse Cyp4x1
fusion protein was used to raise antisera in rabbit,

which were able to detect  1 ng of the antigen (data
not shown). As shown in Fig. 5B, antisera detected a
principal protein band of  55 kDa in brain micro-
A
B
Fig. 2. Modelling of human CYP4x1. (A)
Sequence alignment of CYP4x1 with the
bacterial crystal structure, CYP102 (PDB
code 1FAG, chain B). Highlighted regions in
green represent a-helix and red regions rep-
resent b-sheet (predicted in the case of
CYP4x1 and known for the crystal structure
in the case of CYP102). Numbers at the
side of the alignment represent the residue
number. (B) Molecular model of the predic-
ted active site cavity for CYP4x1, produced
using
GRASP [46] and colour-coded by elec-
trostatic potential (red: negative, blue: posit-
ive). For clarity, only the position of the
haem is shown.
M. Al-Anizy et al. Cyp4x1 in mouse brain
FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 939
somes, but not in liver microsomes, although several
other minor bands were detected. This 55-kDa band
was not detected by preimmune serum from the same
rabbits (data not shown). To determine if this represen-
ted specific binding, the antisera were preincubated
with purified recombinant Cyp4x1 protein, resulting in
the ablation of detection of the 55-kDa protein in brain

(Fig. 5C). This shows that the antisera specifically
detect the murine Cyp4x1 protein. Serial dilution of the
purified recombinant antigen and brain microsomes
showed that there is  10 ng Cyp4x1 proteinÆmg
)1
brain microsomal protein, or 200 pmol Cyp4x1Æmg
)1
microsomal protein (Fig. 5D). This suggests that
Cyp4x1 is a major brain cytochrome P450 form [23].
Cyp4x1 immunohistochemistry in brain
The primary antiserum was used to locate Cyp4x1
protein by immunocytochemistry of paraformaldehyde
fixed wax embedded sections of 129S4 ⁄ Jae mouse
brain. Specific staining for Cyp4x1 protein was found
in the Purkinje cells of the cerebellum, pyramidal neu-
rons in the dentate gyrus of the hippocampus; cortical
forebrain neurons and those of brain stem nuclei; addi-
tionally choroid epithelial cells of the chroroid plexus
were also stained; (Fig. 6C–H). Control sections of
brain regions incubated without primary antiserum
failed to show specific staining (Fig. 6A) as did sec-
tions incubated with preadsorbed primary antiserum
(Fig. 6B). The brown 3,3¢-diaminobenzidine (DAB)
staining was granular and confined to the cytoplasm
of the cells. Based on their size and shape the cells
labelled in all brain regions appeared to be neurons.
Blood vessels were also stained showing that the vascu-
lar endothelial cells contained cyp4x1 protein.
Discussion
The conserved sequence identified by Heng [4] is speci-

fic for the CYP4 family, detecting numerous members
of this family. The sequence at amino acids 124–158
has been modelled to contain the C-helix [30,31], with
conserved residues contacting the I-helix (C.A. Laugh-
ton, D.R. Bell, unpublished data). The high conser-
vation of this region is evidenced by the specific
detection of cytochromes P450, and in particular,
members of the CYP4 family. It was therefore of great
interest when two human ESTs were detected, corres-
ponding to a novel cytochrome P450. Cloning of the
full-length cDNA revealed that the corresponding pro-
tein was a member of a new subfamily, CYP4x1, and
showed high sequence identity to the previously repor-
ted rat CYP4x1 sequence [26], and perfect identity to
the protein sequence reported by Savas [25].
The predicted protein sequence shows the expected
features of a cytochrome P450, including the canonical
haem-binding cysteine motif, and conservation of
other conserved features [30,31]. Molecular modelling
confirmed that the sequence has a primary structure
consistent with a functional, P450 structural fold. The
CYP4x1 and CYP102 sequences can be aligned with
A
B
Fig. 3. Northern blotting of human CYP4x1 RNA. (A) Approximately
1 lg of each poly A+ RNA was run on a denaturing 1% agarose
gel. The tracks are: 1, brain; 2, heart; 3, skeletal muscle; 4, colon;
5, thymus; 6, spleen; 7, kidney; 8, liver; 9, small intestine; 10, pla-
centa; 11, lung; 12, peripheral blood leucocytes. (B) Approximately
2 lg of each poly A+ RNA was run on a denaturing 1% agarose

gel. The tracks are numbered: 1, right ventricle; 2, left ventricle; 3,
right atrium; 4, left atrium; 5, apex of heart; 6, aorta; 7, heart; 8,
foetal heart. Both blots were hybridized with a human CYP4x1
probe, and autoradiographed. The position of the 2.2-kb human
CYP4x1 transcript is indicated by a horizontal line.
Cyp4x1 in mouse brain M. Al-Anizy et al.
940 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
AB
E
DC
Fig. 4. RNAase protection assay for Cyp4x1 RNA in 129S4 ⁄ Jae mice. (A) Cyp4x1 probe was hybridized to 30 lg of yeast tRNA in the pres-
ence (+) or absence (–) of added RNAase, or to 30 lg of Brain (B) or liver (L) RNA for RNAase protection assay. M indicates the 124-base
pair marker transcript (M), the full-length probe is indicated by a line, and the protected fragment is indicated by an arrow. The RNAase pro-
tection assay was performed as described in Experimental procedures, and the dried gel was exposed to film overnight. The vertical line
indicates that several tracks have been removed from the autoradiograph. (B) Animals were treated with vehicle, TCDD, phenobarbital (PB),
ciprofibrate (Cipro) or dexamethasone (Dex), as described in Experimental procedures, RNA isolated from liver, and 30 lg of RNA subjected
to protection assay. The film exposure was for 5 days. (C) Heart, kidney, lung and spleen RNA from each of three animals was analysed for
Cyp4x1 RNA, and a 5-day exposure of the autoradiograph is shown; – and + represent yeast tRNA without and with RNAase treatment. (D)
Thirty milligrams of RNA from pooled aorta from six mice treated with vehicle (Veh) or ciprofibrate (Cip) was analysed by RNAase protection,
and the results of an overnight autoradiograph are shown. (E) RNA was isolated from brain of untreated wild-type (+ ⁄ +) or PPARa nullizy-
gous (– ⁄ –) 129S4 ⁄ Jae mice, and 30 lg of RNA subjected to protection assay. The film exposure was overnight.
M. Al-Anizy et al. Cyp4x1 in mouse brain
FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 941
21% amino acid identity, and good correlation
between observed secondary structural elements in
CYP102 and predicted elements in CYP4x1 (Fig. 2A).
Moreover, this model reveals an extended substrate
binding pocket (Fig. 2B) that suggests that CYP4x1 is
designed to bind substrates distinct in structure from
the medium-chain fatty acids bound by CYP102. The

pocket is approximately L-shaped, with the haem
located at the angle. This suggests that the substrates
may either be shorter chain fatty acids that might bind
in one of two possible orientations, or alternatively
longer-chain fatty acids, but that the oxidation of these
is not directed, as is usually the case in the CYP4s, to
the terminus of their carbon chain, but rather to some
position mid-way along the chain.
Northern blot analysis showed high level expression
of the CYP4x1 RNA in brain and in aorta, and this
was confirmed by analysis of the EST database; this
showed significant numbers of CYP4x1 ESTs in brain
and aorta. An unexpected finding is that there was a
high number of CYP4x1 ESTs from tumour tissue,
suggesting that CYP4x1 may have some role in tumo-
rigenesis.
Further analysis of the function of CYP4x1 was pre-
cluded by the difficulty in obtaining human tissue sam-
ples, and the mouse Cyp4x1 was therefore cloned from
brain RNA of 129S4 ⁄ Jae mice. This sequence had
94% identity to the rat sequence, and was confirmed
as the mouse Cyp4x1 on the basis of sequence identity.
RNAase protection assay showed that the RNA was
expressed at high level in brain and in aorta, but that
there were much lower levels in other tissues. Our
results showed no induction of Cyp4x1 RNA in liver
after treatment with the potent peroxisome prolifera-
tors, ciprofibrate, at a dose which caused liver enlarge-
ment (data not shown). Since this dose of peroxisome
proliferators causes liver enlargement, it is clearly hav-

ing a physiological effect, and so the lack of induction
of Cyp4x1 must reflect a lack of inducibility of this
gene in mouse liver (Fig. 4B). In agreement, there was
no evidence for induction of Cyp4x1 in aorta or brain
(Fig. 4D, and data not shown). This is in contrast to
the work of Savas, who reported that CYP4x1 was
inducible by peroxisome proliferators in human hepa-
toma cells transfected with PPARa [25]; however, it is
widely accepted that human liver cells do not induce
CYP4 genes in response to peroxisome proliferators
[32–34], and so the relevance of their observation is
open to question.
Although the distribution of CYP4x1 RNAs has
been examined, there is no data as to whether the
corresponding protein is translated in vivo. An antibody
specific for the mouse Cyp4x1 protein was developed,
as an antibody raised against human CYP4x1 showed
poor cross-reactivity against recombinant expressed
mouse Cyp4x1. The antibody detected 1 ng of recom-
binant antigen (data not shown), and detected a protein
of  55 kDa in brain microsomes, but failed to detect
M B U P S 4x
43
66
97
116
A
C
B
M 5 10 5 10 5 10 5 10 µg

Brain Liver Liver Brain
α-mCyp4x1 pre-adsorbed
30 10
ng
Cyp4x1
3 1 0.5 0.1
µg microsomes
Fig. 5. Western blotting for mouse Cyp4x1. (A) Expression and
purification of the Cyp4x1 antigen. Total protein from BL21(DE3)
cells (B) or uninduced cells containing the pRSET-mCyp4x1 (U), the
10 000-g pellet from cells induced for 3 h with 1 mm isopropyl
thio-b-
D-galactoside (P), and the proteins solubilized from the pellet
by extraction with 8
M urea (S) were prepared as described
in Experimental procedures, and 20 lg electrophoresed on an
SDS ⁄ PAGE gel. Cyp4x antigen purified on a nickel-affinity column
is shown in track 4x. The molecular mass of markers (M) is shown
in kDa. (B) Western blotting for mCyp4x1. Five and 10 lg brain and
liver microsomes were eletrophoresed on SDS ⁄ PAGE, blotted and
developed with antimCyp4x1 antibody, or antibody that had been
preadsorbed with 80 lg of the mCyp4x1 antigen. The marker (M)
is the histidine-tagged mCyp4x1 protein, and its mobility is indica-
ted by a line; the mobility of the Cyp4x1 specific band is indicated
by an arrow. (C) Quantification of Cyp4x1 in brain microsomes.
Thirty and 10 ng of purified recombinant Cyp4x1 was run on the
same gel as the indicated amount of brain microsomes, western
blotted and chemiluminescence recorded on film. The mobility of
histidine-tagged Cyp4x1 antigen is indicated by a line; the mobility
of the Cyp4x1-specific band is indicated by an arrow.

Cyp4x1 in mouse brain M. Al-Anizy et al.
942 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
A
B
C
D
E
F
G
H
Fig. 6. Immunohistochemistry of Cyp4x1 in mouse brain. Male 129S4 ⁄ Jae mice were killed, and brain taken and fixed, and sections ana-
lysed by immunohistochemistry with an antibody against Cyp4x1, as described in Experimental procedures; staining shows as a brown
deposit. (A) No primary antibody. (B) Primary antibody was preadsorbed with Cyp4x1 antigen. (C) Dentate cells of the hippocampus. (D)
Outer layer of the hippocampus. (E) Choroid plexus. (F) Purkinje cells. (G) Brain stem. (H) Cerebral cortex. A scale bar is shown.
M. Al-Anizy et al. Cyp4x1 in mouse brain
FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 943
this protein in liver microsomes (Fig. 5B), consistent
with the expected size of the P450, and the pattern of
distribution of the corresponding mRNA. The 55-kDa
protein was not detected by preimmune serum suggest-
ing that this is a specific reaction. To confirm this, the
antiserum was preadsorbed with the recombinant
Cyp4x1 antigen, and this ablated binding to the 55-kDa
protein, confirming that this protein is Cyp4x1. Serial
dilution of the Cyp4x1 protein showed that there is
 200 pmols of Cyp4x1Æmg
)1
microsomal protein; this
must be contrasted with the total P450 content of rat
brain, at  100 pmolsÆmg

)1
of microsomal protein. It
has previously been shown that P450 may be present as
both the holoenzyme and the apoenzyme; however, we
have not determined how much of the mouse Cyp4x1
protein is present as holoenzyme in mouse brain.
Further characterization of the Cyp4x1 in mouse
brain showed that the P450 was expressed in the cyto-
plasm of neurons in the cerebellum, and in the vascu-
lar endothelium. This staining could be shown to be
specific for Cyp4x1, as controls lacking primary anti-
body, or which had been preadsorbed with excess
Cyp4x1 antigen, showed no specific staining of these
cells; additionally, there was specificity in the staining
of neuronal cells in the cerebellum, as Purkinje cells
were not stained for Cyp4x1. These results extend and
confirm a previous report of localization of CYP4x1
RNA in rat brain [26].
The high level expression of Cyp4x1 in brain and
aorta begs the question of the functionality of this pro-
tein, and its physiological role. We aim to conduct future
experiments to determine the enzymatic activity of this
P450, and how this relates to physiological function.
Experimental procedures
Animals and tissue
Human cardiovascular system and 12-lane multitissue nor-
thern blots, human aorta cDNA library and RACE ready
aorta cDNA were obtained from Clontech (Oxford, UK).
Human IMAGE clones ID 139602 and 119884 were
obtained from ATCC (LGC Promochem, Teddington, UK).

129S4 ⁄ Jae PPARa+ ⁄ + and 129S4 ⁄ Jae PPARa– ⁄ – mice
were obtained from J.M. Peters (Department of Veterinary
Science, Pennsylvania State University, PY, USA) [29,35],
and maintained as a colony in house; animals were regularly
genotyped for PPARa status [5]. Vehicle treated mice (n ¼
3) received a single dose by gavage of 10 mLÆkg
)1
of corn
oil, containing 2.5% (v ⁄ v) p-dioxane, and mice treated with
2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) received the
same vehicle, but containing 50 lg TCDDÆkg
)1
bodyweight.
Phenobarbital was administered in saline as an i.p. injection
of 80 mgÆkg
)1
bodyweight daily for 3 days; ciprofibrate and
dexamethasone were dissolved in corn oil, dosed at
50 mgÆkg
)1
bodyweight by gavage daily for 3 days; all ani-
mals were killed on day 4. Tissues were frozen in liquid N
2
,
prior to storage at )80° C for the isolation of RNA by the
Triazol method (Invitrogen), or used directly for the prepar-
ation of microsomes. New Zealand White rabbits were used
for immunization with Freund’s incomplete adjuvant, and
subsequent monthly boosters.
All experiments on animals were conducted under the

authority of a project licence granted by the Home Office
to D.R. Bell, in accordance with UK law.
cDNA cloning
EST cDNA clones for R53456 and AA337301 were
obtained from HGMP (Hinxton, Cambridgeshire, UK),
and sequenced on both strands. The latter clone was diges-
ted with EcoRI and the 1.2-kb fragment was radiolabelled
with random primers for screening an aorta cDNA library.
Full-length clones were confirmed by sequencing. For pro-
duction of human CYP4x1 antigen, the cDNA was digested
with BamHI and BstBI, and the fragment cloned into pRS-
ETc (Invitrogen) for expression of amino acids 327–509 of
CYP4x1 as an N-terminally histidine-tagged fusion protein
in bacteria.
A probe for RNAase protection for mouse Cyp4x1 was
obtained by PCR of brain RNA with primers 4x1-12-pF,
5¢-CATGGACATAAGTCCTTTTCCCTTCCTCCT-3¢, and
4x1-12-pR, 5¢-AAACATAAATTTCGCCATTTCTCCTAG
TAT-3¢. The full-length mouse cDNA was obtained with
primers 4x1-f-pF, 5¢-ATGGAGGCCTCCTGGCTGGAG
ACTCGTTGG-3¢ and 4x1-f-pR, 5¢-AAACATAAATTT
CGCCATTTCTCCTAGTAT-3¢. Total RNA from mouse
brain was used, and ProSTAR UltraHF RT ⁄ PCR Kit was
used to generate the first strand cDNA. PCR products were
cloned into pGEM-T (Promega), and sequenced on both
strands. The full-length clone was cloned into pRSETa for
bacterial expression of antigen. Antigen was expressed by
recombinant expression in BL21(DE3) bacteria (Novagen,
Merck Biosciences, Nottingham, UK), and affinity purifica-
tion of pelleted insoluble protein in 8 m urea.

RNAase protection
The RNase protection assay used the Riboquant
Ò
kit, from
PharMingen Ltd (Oxford, UK), according to the manufac-
turer’s instructions. Briefly, template DNA was linearized
with NcoI, then transcribed using [a-
32
P]CTP. The probe
was treated with DNAse I, then proteinase K, phenol ⁄ chlo-
roform extraction, and ammonium acetate ⁄ ethanol precipi-
tation. Thirty micrograms of each RNA sample was
precipitated, resuspended with 8 lL hybridization buffer,
1 lL of synthesized probe added, then incubated overnight
Cyp4x1 in mouse brain M. Al-Anizy et al.
944 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
at 56 °C. The samples were treated for 45 min at 42 °C
with 100 lL RNase cocktail, except the positive control
(–ve tRNA) which was treated with 100 lL buffer. Eighteen
microlitres of proteinase k cocktail were added and the
reactions were incubated for 15 min at 42 °C. Samples were
extracted with phenol ⁄ chloroform, then ethanol precipita-
ted and electrophoresed on a denaturing 6% acrylamide
gel, followed by autoradiography.
Western blotting
Western blotting was performed essentially as described
[36]. For preabsorption with antigen, the antisera was dilu-
ted 1 : 500 in Tris-buffered saline pH 7.4, containing 0.1%
Tween and 10% Marvel, then 50 lg purified Cyp4x1 anti-
gen were added, followed by incubation for 1 h at 4 °C.

The same procedure was followed without the addition of
antigen for the nonpreadsorbed antisera. These antisera
were then used as primary antisera in the western blotting
process.
Microsome preparation
Organs were homogenized in a motor-driven Teflon pestle
and glass tube in ice-cold 0.15 m NaCl, 10 mm KH
2
PO
4
,
pH 7.4. After centrifugation for 10 min at 10 000 g, sam-
ples were centrifuged at 400 000 g for 30 min, and the pel-
let resuspended in 20% glycerol (w ⁄ v), 0.1 m KH
2
PO
4
,
pH 7.4. Samples were normalized by Bradford assay, relat-
ive to BSA.
Immunohistochemistry
The brains were fixed for immunocytochemistry by trans-
cardiac perfusion of anesthetized male 129S4 ⁄ Jae mice
(lethal dose of Nembutal i.p.) firstly by prewash saline solu-
tion at 37 °C followed by 4% freshly prepared paraformal-
dehyde in 0.1 m phosphate buffer pH 7.4 at 5 °C. The
brains were dissected out and embedded in paraffin wax.
Sections of 10 lm thickness were cut and de-waxed prior to
incubation with primary antibody.
The antigen was visualized using the horseradish peroxi-

dase (HRP) secondary antibody system from DAKO
LSAB2 kit (DakoCytomation, Ely, UK) using the bio-
tin ⁄ streptavidin system with DAB (DakoCytomation) as
chromogen. The sections were preincubated for 10 min in
hydrogen peroxide to quench endogenous peroxidases and
blocking serum then incubated with primary antibody for
2 h followed by HRP-labelled secondary antibody (LSAB 2
kit) and finally incubated with DAB solution for 10 min.
The sections were mounted in Vectashield prior to examina-
tion in a computer linked Leitz photo-microscope (Leica
Microsystems, Milton Keynes, UK). The negative control
sections were incubated without primary antibody or with
primary antiserum preadsorbed with purified P450 Cyp4x1
protein and treated as for test sections.
Molecular modelling
The alignment of the CYP4x1 and CYP102 amino acid
sequences was performed using clustalw [37] and refined
manually in the light of the comparison of secondary struc-
ture data ) from the crystal structure in the case of
CYP102 – and predicted using jpred [38] in the case of
CYP4x1. Coordinates for the main chain atoms of aligned
CYP4x1 residues were taken directly from their CYP102
counterparts, and initial side chain coordinates were
assigned using the rules of Summers and Karplus [39].
Main chain coordinates for residues in loops were obtained
using the search method implemented in sybyl (Tripos
Inc., St Louis, MO, USA). All side chain conformations
were then re-predicted using rascle, in-house software
based on the method of local environment similarity [40].
Finally, the model was refined by molecular mechanics

using amber [41]. The quality of the model was checked
using procheck [42] and prosaii [43]. Two further models
were also built, to check consistency in the predictions.
Model 2 used an alternative approach, scwrl [44], for the
side chain prediction; model 3 used the modeller [45]
package throughout, from the point of the sequence align-
ment. The three final models all showed the same general
features with regard to the shape and size of the binding
cavity, so only results for model 1 are shown here.
Acknowledgements
Mohammed Al-anazy was supported by a scholarship
from the Saudi government, and this work was
supported by a grant from the Wellcome trust
(054778 ⁄ Z ⁄ 98). We wish to thank Declan Brady for
invaluable technical support and assistance.
References
1 Nelson DR et al. (1996) P450 superfamily: Update on
new sequences, gene mapping, accession numbers and
nomenclature. Pharmacogenetics 6, 1–42.
2 Coon MJ (2005) Cytochrome P450: Nature’s most ver-
satile biological catalyst. Annual Review of. Pharmacol
Toxicol 45, 1–25.
3 Bell DR et al. (1993) Species-specific induction of cyto-
chrome-P-450 4a-RNAs ) PCR cloning of partial guinea-
pig, human and mouse Cyp4a-cDNAs. Biochem J 294,
173–180.
4 Heng YM, Kuo CWS, Jones PS, Savory R, Schulz RM,
Tomlinson SR, Gray TJB & Bell DR (1997) A novel
murine P-450 gene, Cyp4a14, is part of a cluster of
M. Al-Anizy et al. Cyp4x1 in mouse brain

FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 945
Cyp4a and Cyp4b but not of CYP4F, genes in mouse
and humans. Biochem J 325, 741–749.
5 Jeffery B et al. (2004) Peroxisome proliferator activated
receptor alpha regulates a male-specific cytochrome
P450 in mouse liver. Arch Biochem Biophys 429, 231–
236.
6 Hoch U, Falck JR & de Montellano PRO (2000) Mole-
cular basis for the omega-regiospecificity of the
CYP4A2 and CYP4A3 fatty acid hydroxylases. J Biol
Chem 275, 26952–26958.
7 Cheesman MJ, Baer BR, Zheng YM, Gillam EMJ &
Rettie AE (2003) Rabbit CYP4B1 engineered for high-
level expression in Escherichia coli: ligand stabilization
and processing of the N-terminus and heme prosthetic
group. Arch Biochem Biophys 416, 17–24.
8 Zheng YM, Fisher MB, Yokotani N, Fujii-Kuriyama Y
& Rettie AE (1998) Identification of a meander region
proline residue critical for heme binding to cytochrome
P450: Implications for the catalytic function of human
CYP4B1. Biochemistry 37, 12847–12851.
9 Xu FY, Falck JR, de Montellano PRO & Kroetz DL
(2004) Catalytic activity and isoform-specific inhibition
of rat cytochrome P4504F enzymes. J Pharmacol Exp
Therapeutics 308, 887–895.
10 Kikuta Y, Kusunose E, Kondo T, Yamamoto S,
Kinoshita H & Kusunose M (1994) Cloning and expres-
sion of a novel form of leukotriene B-4 omega-hydroxy-
lase from human liver. Febs Lett 348, 70–74.
11 Capdevila JH, Harris RC & Falck JR (2002) Microso-

mal cytochrome P450 and eicosanoid metabolism. Cell
Mol Life Sci 59, 780–789.
12 Capdevila JH, Nakagawa K & Holla V (2003) In
Advances in Prostaglandin, Leukotriene, and Other
Bioactive Lipid Research: Basic Science and Clinical
Applications, Vol. 525, pp. 39–46.
13 Holla VR, Adas F, Imig J, Zhao XY, Price E, Olsen N,
Kovacs WJ, Magnuson MA, Keeney DS & Breyer MD
et al. (2001) Alterations in the regulation of androgen-
sensitive Cyp 4a monooxygenases cause hypertension.
Proc Natl Acad Sci USA 98, 5211–5216.
14 Schwartzman ML, Balazy M, Masferrer J, Abraham
NG, McGiff JC & Murphy RC (1987) 12 (R)-hydroxy-
icosatetraenoic acid – a cytochrome-P450-dependent
Arachidonate metabolite that inhibits Na+,K+-ATP-
ase in the cornea. Proc Natl Acad Sci USA 84, 8125–
8129.
15 Harder DR, Roman RJ & Gebremedhin D (2000)
Molecular mechanisms controlling nutritive blood flow:
role of cytochrome P450 enzymes. Acta Physiol Scand
168, 543–549.
16 Escalante B, Omata K, Sessa W, Lee SG, Falck JR &
Schwartzman ML (1993) 20-Hydroxyeicosatetraenoic
Acid Is An Endothelium-Dependent Vasoconstrictor In
Rabbit Arteries. Eur J Pharmacol 235, 1–7.
17 Hedlund E, Gustafsson JA & Warner M (2001) Cyto-
chrome P450 in the brain; A review. Curr Drug Metab
2, 245–263.
18 Alexander JJ, Snyder A & Tonsgard JH (1998) Omega-
oxidation of monocarboxylic acids in rat brain. Neuro-

chem Res 23, 227–233.
19 Warner M, Hellmold H, Yoshida S, Liao DZ, Hedlund
E & Gustafsson JA (1997) Cytochrome P450 in the
breast and brain: role in tissue-specific activation of
xenobiotics. Mutat Res 376, 79–85.
20 Hiroi T, Imaoka S & Funae Y (1998) Dopamine forma-
tion from tyramine by CYP2D6. Biochem Biophys Res
Comms 249, 838–843.
21 Bornheim LM, Kim KY, Chen BL & Correia MA
(1995) Microsomal cytochrome P450-mediated liver and
brain anandamide metabolism. Biochem Pharmacol 50,
677–686.
22 Strobel HW, Thompson CM & Antonovic L (2001)
Cytochromes P450 in brain: Function and significance.
Curr Drug Metab 2, 199–214.
23 Bhagwat SV, Boyd MR & Ravindranath V (1995) Rat-
Brain Cytochrome-P450 – reassessment of monooxyge-
nase activities and cytochrome-P450 Levels. Drug
Metabolism Disposition 23, 651–654.
24 Warner M & Gustafsson JA (1994) Effect of ethanol on
cytochrome-P450 in the rat brain. Proc Natl Acad Sci
USA 91, 1019–1023.
25 Savas O, Hsu MH, Griffin KJ, Bell DR & Johnson EF
(2005) Conditional regulation of the human CYP4X1
and CYP4Z1 genes. Arch Biochem Biophys 436, 377–385.
26 Bylund J, Zhang CY & Harder DR (2002) Identification
of a novel cytochrome P450, CYP4X1, with unique
localization specific to the brain. Biochem Biophys Res
Comms 296, 677–684.
27 Li HY & Poulos TL (1997) The structure of the cyto-

chrome p450BM-3 haem domain complexed with the
fatty acid substrate, palmitoleic acid. Nature Struct Biol
4, 140–146.
28 Bell DR & Elcombe CR (1991) Regulation of differen-
tially spliced transcripts of acyl-CoA oxidase in the rat.
Biochimica Biophysica Acta 1090, 211–215.
29 Lee SST, Pineau T, Drago J, Lee EJ, Owens JW,
Kroetz DL, Fernandezalguero PM, Westphal H &
Gonzalez FJ (1995) Targeted Disruption of the alpha-
isoform of the peroxisome proliferator-activated recep-
tor gene in mice results in abolishment of the pleiotropic
effects of peroxisome proliferators. Mol Cell Biol 15,
3012–3022.
30 Peterson JA & Graham SE (1998) A close family
resemblance: the importance of structure in under-
standing cytochromes P450. Structure Fold Design 6,
1079–1085.
31 Hasemann CA, Kurumbail RG, Boddupalli SS, Peter-
son JA & Deisenhofer J (1995) Structure and function
Cyp4x1 in mouse brain M. Al-Anizy et al.
946 FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS
of cytochromes-P450 – a comparative-analysis of 3 crys-
tal-structures. Structure 3, 41–62.
32 Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J,
Odum J, Tugwood JD, Kettle S & Purchase IFM (1994)
Mechanistically-based human hazard assessment of per-
oxisome proliferator-induced hepatocarcinogenesis.
Human Exp Toxicol 13, S1–S117.
33 Elcombe CR, Bell DR, Elias E, Hasmall SC & Plant NJ
(1996) In Peroxisomes: Biology and Role in Toxicology

and Disease, Vol. 804, pp. 628–635.
34 Palmer CNA, Hsu MH, Griffin KJ, Raucy JL & John-
son EF (1998) Peroxisome proliferator activated recep-
tor-alpha expression in human liver. Mol Pharmacol 53,
14–22.
35 Akiyama TE et al. (2001) Peroxisome proliferator-acti-
vated receptor-alpha regulates lipid homeostasis, but is
not associated with obesity – studies with congenic
mouse lines. Journal of. Biol Chem 276, 39088–39093.
36 Bell AR, Savory R, Horley NJ, Choudhury AI, Dickins
M, Gray TJB, Salter AM & Bell DR (1998) Molecular
basis of non-responsiveness to peroxisome proliferators:
the guinea-pig PPAR alpha is functional and mediates
peroxisome proliferator-induced hypolipidaemia. Bio-
chem J 332, 689–693.
37 Thompson JD, Higgins DG & Gibson TJ (1994) clus-
tal w: improving the sensitivity of progressive multiple
sequence alignment through sequence weighting, posi-
tion-specific gap penalties and weight matrix choice.
Nucl Acids Res 22, 4673–4680.
38 Cuff JA, Clamp ME, Siddiqui AS, Finlay M & Barton
GJ (1998) JPred: a consensus secondary structure pre-
diction server. Bioinformatics 14, 892–893.
39 Summers NL & Karplus M (1989) Construction of side-
chains in homology modeling. Application to the
C-terminal lobe of rhizopuspepsin. J Mol Biol 210 ,
785–811.
40 Laughton CA (1994) Prediction of protein side-chain
conformations from local 3-dimensional homology rela-
tionships. J Mol Biol 235, 1088–1097.

41 Pearlman DA, Case DA, Caldwell JW, Ross WR, Chea-
tham TE III, DeBolt S, Ferguson D, Seibel G & Koll-
man P (1995) AMBER, a computer program for
applying molecular mechanics, normal mode analysis,
molecular dynamics and free energy calculations to elu-
cidate the structures and energies of molecules. Comp
Phys Commun 91, 1–41.
42 Laskowski RA, Macarthur MW, Moss DS & Thornton
JM (1993) Procheck – a program to check the stereo-
chemical quality of protein structures. J Appl Crystal-
logr 26, 283–291.
43 Sippl MJ (1993) Recognition of errors in 3-dimensional
structures of proteins. Proteins-Structure Function Genet
17, 355–362.
44 Bower MJ, Cohen FE & Dunbrack RL (1997) Predic-
tion of protein side-chain rotamers from a backbone-
dependent rotamer library: a new homology modeling
tool. J Mol Biol 267, 1268–1282.
45 Sali A & Blundell TL (1993) Comparative protein mod-
elling by satisfaction of spatial restraints. J Mol Biol
234, 779–815.
46 Nicholls A, Sharp KA & Honig B (1991) Protein fold-
ing and association – insights from the interfacial and
thermodynamic properties of hydrocarbons. Proteins-
Structure Function Genet 11, 281–296.
Supplementary material
The following supplementary material is available
online:
Doc. S1. Pdb file of the human CYP4·1 model. The
model was constructed as described in Experimental

procedures.
This material is available as part of the online article
from
M. Al-Anizy et al. Cyp4x1 in mouse brain
FEBS Journal 273 (2006) 936–947 ª 2006 The Authors Journal compilation ª 2006 FEBS 947